Condition: Breast Cancer · Sponsor: Shanghai Jiao Tong University School of Medicine
The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore whether 4 courses of dual HER2 blockade combined with taxanes can lead to a similar prognosis with current standard treatment, which is one-year trastuzumab monotherapy combined with chemotherapy, while reducing the adverse reactions of treatment.
This description comes directly from the study's public registry record.
Xiaosong Chen · +8621-64370045*602102 · chenxiaosong0156@hotmail.com
Yiwei Tong · +8621-64370045*602107 · ash_yiwei@sjtu.edu.cn
Always discuss trial participation with your own doctor first.
| Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05891561